Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Molecular Cancer
Published in: Molecular Cancer 1/2012

Open Access 01-12-2012 | Research

Cisplatin and ultra-violet-C synergistically down-regulate receptor tyrosine kinases in human colorectal cancer cells

Authors: Junji Kawaguchi, Seiji Adachi, Ichiro Yasuda, Takahiro Yamauchi, Masanori Nakashima, Tomohiko Ohno, Masahito Shimizu, Takashi Yoshioka, Masahiko Itani, Osamu Kozawa, Hisataka Moriwaki

Published in: Molecular Cancer | Issue 1/2012

Login to get access

Abstract

Background

Platinum-containing anti-cancer drugs such as cisplatin are widely used for patients with various types of cancers, however, resistance to cisplatin is observed in some cases. Whereas we have recently reported that high dose UV-C (200 J/m²) induces colorectal cancer cell proliferation by desensitization of EGFR, which leads oncogenic signaling in these cells, in this study we investigated the combination effect of low dose cisplatin (10 μM) and low dose UV-C (10 J/m²) on cell growth and apoptosis in several human colorectal cancer cells, SW480, DLD-1, HT29 and HCT116.

Results

The combination inhibited cell cycle and colony formation, while either cisplatin or UV-C alone had little effect. The combination also induced apoptosis in these cells. In addition, the combination caused the downregulation of EGFR and HER2. Moreover, UV-C alone caused the transient internalization of the EGFR, but with time EGFR recycled back to the cell surface, while cisplatin did not affect its localization. Surprisingly, the combination caused persistent internalization of the EGFR, which results in the lasting downregulation of the EGFR.

Conclusions

The combination of low dose cisplatin and low dose UV-C synergistically exerted anti-cancer effect by down-regulating RTK, such as EGFR and HER2. These findings may provide a novel strategy for the treatment of patients with colorectal cancer.
Appendix
Available only for authorised users
Literature
1.
Hynes NE, Horsch K, Olayioye MA, Badache A: The ErbB receptor tyrosine family as signal integrators. Endocr Relat Cancer. 2001, 8: 151-159. 10.1677/erc.0.0080151CrossRefPubMed
2.
Kuan CT, Wikstrand CJ, Bigner DD: EGF mutant receptor vIII as a molecular target in cancer therapy. Endocr Relat Cancer. 2001, 8: 83-96. 10.1677/erc.0.0080083CrossRefPubMed
3.
Zandi R, Larsen AB, Andersen P, Stockhausen MT, Poulsen HS: Mechanisms for oncogenic activation of the epidermal growth factor receptor. Cell Signal. 2007, 19: 2013-2023. 10.1016/j.cellsig.2007.06.023CrossRefPubMed
4.
Nakashima M, Adachi S, Yasuda I, Yamauchi T, Kozawa O, Moriwaki H: Rho-kinase regulates negatively the epidermal growth factor-stimulated colon cancer cell proliferation. Int J Oncol. 2010, 36: 585-592.PubMed
5.
Borg A, Linell F, Idvall I, Johansson S, Sigurdsson H, Ferno M, Killander D: HER2/neu amplification and comedo type breast carcinoma. Lancet. 1989, 1: 1268-1269.CrossRefPubMed
6.
Shepard HM, Lewis GD, Sarup JC, Fendly BM, Maneval D, Mordenti J, Figari I, Kotts CE, Palladino MA, Ullrich A: Monoclonal antibody therapy of human cancer: taking the HER2 protooncogene to the clinic. J Clin Immunol. 1991, 11: 117-127. 10.1007/BF00918679CrossRefPubMed
7.
Shimizu M, Deguchi A, Lim JT, Moriwaki H, Kopelovich L, Weinstein IB: (−)-Epigallocatechin gallate and polyphenon E inhibit growth and activation of the epidermal growth factor receptor and human epidermal growth factor receptor-2 signaling pathways in human colon cancer cells. Clin Cancer Res. 2005, 11: 2735-2746. 10.1158/1078-0432.CCR-04-2014CrossRefPubMed
8.
Feng FY, Varambally S, Tomlins SA, Chun PY, Lopez CA, Li X, Davis MA, Chinnaiyan AM, Lawrence TS, Nyati MK: Role of epidermal growth factor receptor degradation in gemcitabine-mediated cytotoxicity. Oncogene. 2007, 26: 3431-3439. 10.1038/sj.onc.1210129CrossRefPubMed
9.
Masuda M, Suzui M, Weinstein IB: Effects of epigallocatechin-3-gallate on growth, epidermal growth factor receptor signaling pathways, gene expression, and chemosensitivity in human head and neck squamous cell carcinoma cell lines. Clin Cancer Res. 2001, 7: 4220-4229.PubMed
10.
Siddik ZH: Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene. 2003, 22: 7265-7279. 10.1038/sj.onc.1206933CrossRefPubMed
11.
Parker LJ, Italiano LC, Morton CJ, Hancock NC, Ascher DB, Aitken JB, Harris HH, Campomanes P, Rothlisberger U, De Luca A: Studies of glutathione transferase P1-1 bound to a platinum(IV)-based anticancer compound reveal the molecular basis of its activation. Chemistry. 2011, 17: 7806-7816. 10.1002/chem.201100586CrossRefPubMed
12.
Muscella A, Urso L, Calabriso N, Vetrugno C, Fanizzi FP, Storelli C, Marsigliante S: Functions of epidermal growth factor receptor in cisplatin response of thyroid cells. Biochem Pharmacol. 2009, 77: 979-992. 10.1016/j.bcp.2008.12.001CrossRefPubMed
13.
Ahsan A, Hiniker SM, Ramanand SG, Nyati S, Hegde A, Helman A, Menawat R, Bhojani MS, Lawrence TS, Nyati MK: Role of epidermal growth factor receptor degradation in cisplatin-induced cytotoxicity in head and neck cancer. Cancer Res. 2010, 70: 2862-2869. 10.1158/0008-5472.CAN-09-4294PubMedCentralCrossRefPubMed
14.
Winograd-Katz SE, Levitzki A: Cisplatin induces PKB/Akt activation and p38(MAPK) phosphorylation of the EGF receptor. Oncogene. 2006, 25: 7381-7390. 10.1038/sj.onc.1209737CrossRefPubMed
15.
Benhar M, Dalyot I, Engelberg D, Levitzki A: Enhanced ROS production in oncogenically transformed cells potentiates c-Jun N-terminal kinase and p38 mitogen-activated protein kinase activation and sensitization to genotoxic stress. Mol Cell Biol. 2001, 21: 6913-6926. 10.1128/MCB.21.20.6913-6926.2001PubMedCentralCrossRefPubMed
16.
Latonen L, Laiho M: Cellular UV damage responses-functions of tumor suppressor p53. Biochim Biophys Acta. 2005, 1755: 71-89.PubMed
17.
Olsen BB, Neves-Petersen MT, Klitgaard S, Issinger OG, Petersen SB: UV light blocks EGFR signalling in human cancer cell lines. Int J Oncol. 2007, 30: 181-185.PubMed
18.
Kim SC, Park SS, Lee YJ: Effect of UV irradiation on colorectal cancer cells with acquired TRAIL resistance. J Cell Biochem. 2008, 104: 1172-1180. 10.1002/jcb.21682CrossRefPubMed
19.
Petersen MT, Jonson PH, Petersen SB: Amino acid neighbours and detailed conformational analysis of cysteines in proteins. Protein Eng. 1999, 12: 535-548. 10.1093/protein/12.7.535CrossRefPubMed
20.
Prompers JJ, Hilbers CW, Pepermans HA: Tryptophan mediated photoreduction of disulfide bond causes unusual fluorescence behaviour of Fusarium solani pisi cutinase. FEBS Lett. 1999, 456: 409-416. 10.1016/S0014-5793(99)00990-4CrossRefPubMed
21.
Neves-Petersen MT, Gryczynski Z, Lakowicz J, Fojan P, Pedersen S, Petersen E, Bjorn Petersen S: High probability of disrupting a disulphide bridge mediated by an endogenous excited tryptophan residue. Protein Sci. 2002, 11: 588-600.PubMedCentralCrossRefPubMed
22.
Vanhooren A, Devreese B, Vanhee K, Van Beeumen J, Hanssens I: Photoexcitation of tryptophan groups induces reduction of two disulfide bonds in goat alpha-lactalbumin. Biochemistry. 2002, 41: 11035-11043. 10.1021/bi0258851CrossRefPubMed
23.
Neves-Petersen MT, Snabe T, Klitgaard S, Duroux M, Petersen SB: Photonic activation of disulfide bridges achieves oriented protein immobilization on biosensor surfaces. Protein Sci. 2006, 15: 343-351. 10.1110/ps.051885306PubMedCentralCrossRefPubMed
24.
Neves-Petersen MT, Duroux M, Skovsen E, Duroux L, Petersen SB: Printing novel molecular architectures with micrometer resolution using light. J Nanosci Nanotechnol. 2009, 9: 3372-3381. 10.1166/jnn.2009.NS04CrossRefPubMed
25.
Neves-Petersen MT, Klitgaard S, Pascher T, Skovsen E, Polivka T, Yartsev A, Sundstrom V, Petersen SB: Flash photolysis of cutinase: identification and decay kinetics of transient intermediates formed upon UV excitation of aromatic residues. Biophys J. 2009, 97: 211-226. 10.1016/j.bpj.2009.01.065PubMedCentralCrossRefPubMed
26.
Adachi S, Yasuda I, Nakashima M, Yamauchi T, Kawaguchi J, Shimizu M, Itani M, Nakamura M, Nishii Y, Yoshioka T: Ultraviolet irradiation can induce evasion of colon cancer cells from stimulation of epidermal growth factor. J Biol Chem. 2011, 286: 26178-26187. 10.1074/jbc.M111.240630PubMedCentralCrossRefPubMed
27.
Sorenson CM, Barry MA, Eastman A: Analysis of events associated with cell cycle arrest at G2 phase and cell death induced by cisplatin. J Natl Cancer Inst. 1990, 82: 749-755. 10.1093/jnci/82.9.749CrossRefPubMed
28.
29.
Hoffman RM: In vitro sensitivity assays in cancer: a review, analysis, and prognosis. J Clin Lab Anal. 1991, 5: 133-143. 10.1002/jcla.1860050211CrossRefPubMed
30.
Boulares AH, Yakovlev AG, Ivanova V, Stoica BA, Wang G, Iyer S, Smulson M: Role of poly(ADP-ribose) polymerase (PARP) cleavage in apoptosis. Caspase 3-resistant PARP mutant increases rates of apoptosis in transfected cells. J Biol Chem. 1999, 274: 22932-22940. 10.1074/jbc.274.33.22932CrossRefPubMed
31.
Kapitanovic S, Radosevic S, Kapitanovic M, Andelinovic S, Ferencic Z, Tavassoli M, Primorac D, Sonicki Z, Spaventi S, Pavelic K, Spaventi R: The expression of p185(HER-2/neu) correlates with the stage of disease and survival in colorectal cancer. Gastroenterology. 1997, 112: 1103-1113. 10.1016/S0016-5085(97)70120-3CrossRefPubMed
32.
Mendelsohn J, Baselga J: The EGF receptor family as targets for cancer therapy. Oncogene. 2000, 19: 6550-6565. 10.1038/sj.onc.1204082CrossRefPubMed
33.
Zwang Y, Yarden Y: p38 MAP kinase mediates stress-induced internalization of EGFR: implications for cancer chemotherapy. Embo J. 2006, 25: 4195-4206. 10.1038/sj.emboj.7601297PubMedCentralCrossRefPubMed
34.
Ciccarelli RB, Solomon MJ, Varshavsky A, Lippard SJ: In vivo effects of cis- and trans-diamminedichloroplatinum(II) on SV40 chromosomes: differential repair, DNA-protein cross-linking, and inhibition of replication. Biochemistry. 1985, 24: 7533-7540. 10.1021/bi00347a005CrossRefPubMed
35.
Salles B, Butour JL, Lesca C, Macquet JP: cis-Pt(NH3)2Cl2 and trans-Pt(NH3)2Cl2 inhibit DNA synthesis in cultured L1210 leukemia cells. Biochem Biophys Res Commun. 1983, 112: 555-563. 10.1016/0006-291X(83)91500-0CrossRefPubMed
36.
Mello JA, Lippard SJ, Essigmann JM: DNA adducts of cis-diamminedichloroplatinum(II) and its trans isomer inhibit RNA polymerase II differentially in vivo. Biochemistry. 1995, 34: 14783-14791. 10.1021/bi00045a020CrossRefPubMed
37.
Sorenson CM, Eastman A: Influence of cis-diamminedichloroplatinum(II) on DNA synthesis and cell cycle progression in excision repair proficient and deficient Chinese hamster ovary cells. Cancer Res. 1988, 48: 6703-6707.PubMed
38.
Nakashima M, Adachi S, Yasuda I, Yamauchi T, Kawaguchi J, Hanamatsu T, Yoshioka T, Okano Y, Hirose Y, Kozawa O, Moriwaki H: Inhibition of Rho-associated coiled-coil containing protein kinase enhances the activation of epidermal growth factor receptor in pancreatic cancer cells. Mol Cancer. 2011, 10: 79- 10.1186/1476-4598-10-79PubMedCentralCrossRefPubMed
39.
Benhar M, Engelberg D, Levitzki A: Cisplatin-induced activation of the EGF receptor. Oncogene. 2002, 21: 8723-8731. 10.1038/sj.onc.1205980CrossRefPubMed
40.
Yoshida T, Okamoto I, Iwasa T, Fukuoka M, Nakagawa K: The anti-EGFR monoclonal antibody blocks cisplatin-induced activation of EGFR signaling mediated by HB-EGF. FEBS Lett. 2008, 582: 4125-4130. 10.1016/j.febslet.2008.11.010CrossRefPubMed
41.
Douillard JY, Siena S, Cassidy J, Tabernero J, Burkes R, Barugel M, Humblet Y, Bodoky G, Cunningham D, Jassem J: Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study. J Clin Oncol. 2010, 28: 4697-4705. 10.1200/JCO.2009.27.4860CrossRefPubMed
42.
Siena S, Peeters M, Van Cutsem E, Humblet Y, Conte P, Bajetta E, Comandini D, Bodoky G, Van Hazel G, Salek T: Association of progression-free survival with patient-reported outcomes and survival: results from a randomised phase 3 trial of panitumumab. Br J Cancer. 2007, 97: 1469-1474. 10.1038/sj.bjc.6604053PubMedCentralCrossRefPubMed
43.
Amado RG, Wolf M, Peeters M, Van Cutsem E, Siena S, Freeman DJ, Juan T, Sikorski R, Suggs S, Radinsky R: Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol. 2008, 26: 1626-1634. 10.1200/JCO.2007.14.7116CrossRefPubMed
44.
Countaway JL, Nairn AC, Davis RJ: Mechanism of desensitization of the epidermal growth factor receptor protein-tyrosine kinase. J Biol Chem. 1992, 267: 1129-1140.PubMed
45.
Theroux SJ, Latour DA, Stanley K, Raden DL, Davis RJ: Signal transduction by the epidermal growth factor receptor is attenuated by a COOH-terminal domain serine phosphorylation site. J Biol Chem. 1992, 267: 16620-16626.PubMed
46.
Adachi S, Shimizu M, Shirakami Y, Yamauchi J, Natsume H, Matsushima-Nishiwaki R, To S, Weinstein IB, Moriwaki H, Kozawa O: (−)-Epigallocatechin gallate downregulates EGF receptor via phosphorylation at Ser1046/1047 by p38 MAPK in colon cancer cells. Carcinogenesis. 2009, 30: 1544-1552. 10.1093/carcin/bgp166CrossRefPubMed
47.
Adachi S, Yasuda I, Nakashima M, Yamauchi T, Yamauchi J, Natsume H, Moriwaki H, Kozawa O: HSP90 inhibitors induce desensitization of EGF receptor via p38 MAPK-mediated phosphorylation at Ser1046/1047 in human pancreatic cancer cells. Oncol Rep. 2010, 23: 1709-1714.PubMed
48.
Kartalou M, Essigmann JM: Mechanisms of resistance to cisplatin. Mutat Res. 2001, 478: 23-43. 10.1016/S0027-5107(01)00141-5CrossRefPubMed
49.
Adachi S, Nagao T, Ingolfsson HI, Maxfield FR, Andersen OS, Kopelovich L, Weinstein IB: The inhibitory effect of (−)-epigallocatechin gallate on activation of the epidermal growth factor receptor is associated with altered lipid order in HT29 colon cancer cells. Cancer Res. 2007, 67: 6493-6501. 10.1158/0008-5472.CAN-07-0411CrossRefPubMed
50.
Adachi S, Nagao T, To S, Joe AK, Shimizu M, Matsushima-Nishiwaki R, Kozawa O, Moriwaki H, Maxfield FR, Weinstein IB: (−)-Epigallocatechin gallate causes internalization of the epidermal growth factor receptor in human colon cancer cells. Carcinogenesis. 2008, 29: 1986-1993. 10.1093/carcin/bgn128PubMedCentralCrossRefPubMed
Metadata
Title
Cisplatin and ultra-violet-C synergistically down-regulate receptor tyrosine kinases in human colorectal cancer cells
Authors
Junji Kawaguchi
Seiji Adachi
Ichiro Yasuda
Takahiro Yamauchi
Masanori Nakashima
Tomohiko Ohno
Masahito Shimizu
Takashi Yoshioka
Masahiko Itani
Osamu Kozawa
Hisataka Moriwaki
Publication date
01-12-2012
Publisher
BioMed Central
Published in
Molecular Cancer / Issue 1/2012
Electronic ISSN: 1476-4598
DOI
https://doi.org/10.1186/1476-4598-11-45

Other articles of this Issue 1/2012

Molecular Cancer 1/2012 Go to the issue

Research

Rab31 expression levels modulate tumor-relevant characteristics of breast cancer cells

Research

Nicotine, IFN-γ and retinoic acid mediated induction of MUC4 in pancreatic cancer requires E2F1 and STAT-1 transcription factors and utilize different signaling cascades

Research

IL-1β promotes stemness and invasiveness of colon cancer cells through Zeb1 activation

Research

The RASSF gene family members RASSF5, RASSF6 and RASSF7 show frequent DNA methylation in neuroblastoma

Research

Inhibition of Phosphodiesterase-4 (PDE4) activity triggers luminal apoptosis and AKT dephosphorylation in a 3-D colonic-crypt model

Research

miR-31 and its host gene lncRNA LOC554202 are regulated by promoter hypermethylation in triple-negative breast cancer
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits